新セフェム系抗生物質CS-807の抗菌力ならびに呼吸器感染症における臨床応用

DOI

書誌事項

タイトル別名
  • ANTIBACTERIAL ACTIVITY OF THE CEPHEM CS-807 AGAINST CLINICAL ISOLATES AND ITS CLINICAL APPLICATION TO RESPIRATORY TRACT INFECTIONS

抄録

We determined to antibacterial activity of CS-807, a newly developed cephem, against clinical isolates and its clinical efficacy in respiratory tract infections with the following results:<BR>1) Antibacterial activity: MIC's of CS-807, cefaclor (OCL) and cefixime (CFIX) against 562 strains isolated from clinical specimens (10 genera and 14 species, including Gram-positive cocci, Gram-negative bacilli and anaerobes) were measured and compared: against S. aureus, CS-807 showed similar activity to that of CCL; the antibacterial activity of CS-807 against such Enterobacteriaceae as E. coli was similar to that of CFIX; it showed weak activity against P. aeruginosa and very low activity against B. fragilis, as its MIC's were higher than 25yeml.<BR>2) Clinical results: when CS-807 was given to six patients with respiratory tract infection (one with bronchopneumonia, Two with bronchiectasis complicated with infection, three with chronic bronchitis) at a daily dose of 200mg (divided into two doses) for 5-7 days, two of the patients showed good and four fair response. As to side-effects, although one patient complained of upper abdominal pain, treatment could be continued, and this symptom rapidly disappeared after termination of treatment. There were no abnormal laboratory findings related to CS-807.<BR>CS-807 is easy to administer because it is given orally, and since it showed powerful activity against Gram-positive cocci, it is considered a useful drug for the treatment of respiratory tract infection.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ